Efficacy and safety of an amino acid jelly containing coenzyme Q10 and l-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01)

Iwase, Satoru; Kawaguchi, Takashi; Yotsumoto, Daisuke; Doi, Takako; Miyara, Kyuichiro; Odagiri, Hiroki; Kitamura, Kenichiro; Ariyoshi, Keisuke; Miyaji, Tempei; Ishiki, Hiroto; Inoue, Kentaro; Tsutsumi, Chizuko; Sagara, Yoshiaki; Yamaguchi, Takuhiro

doi:10.1007/s00520-015-2824-4

Cited by 47 publications

(62 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral nutritional supplements rich in branched‐chain amino acids (Inner Power ® , Otsuka Pharmaceutical Co., Ltd., Japan) were provided for all patients in amounts of one pack daily for 8 weeks. One pack of Inner Power ® (139 kcal/125 g) contains branched‐chain amino acids (2500 mg), coenzyme Q10 (30 mg), and L‐carnitine (50 mg) …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non‐small‐cell lung cancer

Naito

Mitsunaga

Miura

et al. 2018

J cachexia sarcopenia muscle

124

145

View full text Add to dashboard Cite

Background Combinations of exercise and nutritional interventions might improve the functional prognosis for cachectic cancer patients. However, high attrition and poor compliance with interventions limit their efficacy. We aimed to test the feasibility of the early induction of new multimodal interventions specific for elderly patients with advanced cancer Nutrition and Exercise Treatment for Advanced Cancer (NEXTAC) programme. Methods This was a multicentre prospective single‐arm study. We recruited 30 of 46 screened patients aged ≥70 years scheduled to receive first‐line chemotherapy for newly diagnosed, advanced pancreatic, or non‐small‐cell lung cancer. Physical activity was measured using pedometers/accelerometer (Lifecorder ® , Suzuken Co., Ltd., Japan). An 8 week educational intervention comprised three exercise and three nutritional sessions. The exercise interventions combined home‐based low‐intensity resistance training and counselling to promote physical activity. Nutritional interventions included standard nutritional counselling and instruction on how to manage symptoms that interfere with patient's appetite and oral intake. Supplements rich in branched‐chain amino acids (Inner Power ® , Otsuka Pharmaceutical Co., Ltd., Japan) were provided. The primary endpoint of the study was feasibility, which was defined as the proportion of patients attending ≥4 of six sessions. Secondary endpoints included compliance and safety. Results The median patient age was 75 years (range, 70–84). Twelve patients (40%) were cachectic at baseline. Twenty‐nine patients attended ≥4 of the six planned sessions (96.7%, 95% confidence interval, 83.3 to 99.4). One patient dropped out due to deteriorating health status. The median proportion of days of compliance with supplement consumption and exercise performance were 99% and 91%, respectively. Adverse events possibly related to the NEXTAC programme were observed in five patients and included muscle pain (Grade 1 in two patients), arthralgia (Grade 1 in one patient), dyspnoea on exertion (Grade 1 in one patient), and plantar aponeurositis (Grade 1 in one patient). Conclusions The early induction of multimodal interventions showed excellent compliance and safety in elderly patients with newly diagnosed pancreatic and non‐small‐cell lung cancer receiving concurrent chemotherapy. We are now conducting a randomized phase II study to measure the impact of these interventions on functional prognosis.

show abstract

Section: Methodsmentioning

confidence: 99%

“…One pack of Inner Power ® (139 kcal/125 g) contains branched-chain amino acids (2500 mg), coenzyme Q10 (30 mg), and L-carnitine (50 mg). 26,27 Exercise intervention…”

Section: Nutritional Interventionmentioning

confidence: 99%

Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non‐small‐cell lung cancer

Naito

Mitsunaga

Miura

et al. 2018

J cachexia sarcopenia muscle

124

145

View full text Add to dashboard Cite

show abstract

“…aerobics, resistance, and home-based exercise [69–75], and nutraceutical supplements (e.g. lipid replacement therapy [76,77], molecular replacement therapy [47], and l -carnitine and coenzyme Q10 [78]). However, even if non-pharmacological interventions reduced RIF, the mechanism behind the effect of these interventions on CRF remains unclear and the effect sizes of these treatments on CRF are small.…”

Section: Current Treatment Of Rifmentioning

confidence: 99%

The Etiology and management of radiotherapy-induced fatigue

Hsiao

Daly

Saligan

2016

Expert Review of Quality of Life in Cancer Care

View full text Add to dashboard Cite

Fatigue is one of the most common side-effects accompanying radiotherapy, but arguably the least understood. Radiotherapy-induced fatigue (RIF) is a clinical subtype of cancer treatment-related fatigue. It is described as a pervasive, subjective sense of tiredness persisting over time, interferes with activities of daily living, and is not relieved by adequate rest or sleep. RIF is one of the early side-effects and long-lasting for cancer patients treated with localized radiation. Although the underlying mechanisms of fatigue have been studied in several disease conditions, the etiology, mechanisms, and risk factors of RIF remain elusive, and this symptom remains poorly managed. The purpose of this paper is to review and discuss recent articles that defined, proposed biologic underpinnings and mechanisms to explain the pathobiology of RIF, as well as articles that proposed interventions to manage RIF. Understanding the mechanisms of RIF can describe promising pathways to identify at-risk individuals and identify potential therapeutic targets to alleviate and prevent RIF using a multimodal, multidisciplinary approach.

show abstract

“…Another recent trial evaluated an amino acid jelly containing coenzyme Q 10 and l-carnitine in treating fatigue in breast cancer patients receiving chemotherapy [44]. Fifty nine patients were randomized to receive the jelly orally once a day or regular care.…”

Section: • Corticosteroidsmentioning

confidence: 99%

Management of Fatigue Following Breast Cancer Treatment

Roila

Fumi

Fatigoni

2016

Breast Cancer Manag.

View full text Add to dashboard Cite

Cancer-related fatigue (CRF) is a very distressing symptom experienced by most cancer patients. CRF is a complex symptom and there is no agreement regarding the exact definition, the best measurement instrument or even the optimal treatment. CRF is an important problem especially in breast cancer patients, during and after treatment, in long-term survivors. In the last few decades survival rates have dramatically improved. Thus, the number of breast cancer survivors has increased and preservation of quality of life has become very important. This paper is a literature review of the studies published in the last 5 years on management of CRF and breast cancer patients. We distinguished CRF during and after oncological therapy and examined both pharmacological and nonpharmacological interventions.

show abstract

Efficacy and safety of an amino acid jelly containing coenzyme Q10 and l-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01)

Abstract: The registration number of this study in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) is UMIN000008646.

Cited by 47 publications

References 37 publications

Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non‐small‐cell lung cancer

Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non‐small‐cell lung cancer

The Etiology and management of radiotherapy-induced fatigue

Management of Fatigue Following Breast Cancer Treatment

Contact Info

Product

Resources

About